Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum
ConditionEmphysema
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-85
SponsorMcMaster University
About this trial
The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.
Eligibility criteria
Qualifiers
≥40 years of age
Current or ex-smokers with a >10 pack year smoking history
Have a post-bronchodilator forced expired volume in 1 second (FEV1)/forced expired vital capacity (FVC) ratio of <70% and a post-bronchodilator FEV1 value from ≥30% predicted (GOLD 1, 2 and 3), (Global Initiative for Obstructive Lung disease)
Have a radiologist confirmed pulmonary emphysema diagnosis based on CT
Disqualifiers
Patients with other non-COPD airway diseases
Patients with very severe COPD (FEV1<30% predicted)
Patients with an intercurrent exacerbation
Patients with life expectancy less than 3 months
Trial design
Treatments tested in this trial
- Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI
Treatment groups
45 Participants
are divided into 3 treatment groupsSponsors and collaborators
McMaster University
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Collaborator
Source ClinicalTrials.gov